Congenital hydronephrosis
disease diseaseOn this page
Summary
Congenital hydronephrosis (MONDO:0007741) is a disease and 6 clinical trials. Top therapeutic interventions include etomidate, midazolam, and propofol. A subtype of hydronephrosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 6
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | congenital hydronephrosis |
| Mondo ID | MONDO:0007741 |
| Orphanet | 2190 |
| ICD-10-CM | Q62.0 |
| ICD-11 | 808343797 |
| NCIT | C102979 |
| SNOMED CT | 16297002 |
| UMLS | C0266316 |
| MedGen | 78594 |
| MedDRA | 10050975 |
| Is cancer (heuristic) | no |
Data availability: 1 cell line.
Disease family
This is a subtype of hydronephrosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › urinary system disorder › urinary tract obstruction › hydronephrosis › congenital hydronephrosis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 6.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 5 |
| PHASE4 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02013986 | PHASE4 | UNKNOWN | Effects of Etomidate on Postoperative Circadian Rhythm Changes of Salivary Cortisol in Children |
| NCT06921733 | Not specified | RECRUITING | Ultrasound Localization Microscopy in Patient With Congenital Anomalies of the Kidney and Urinary Tract (CAKUT) |
| NCT07382570 | Not specified | NOT_YET_RECRUITING | Natural Course of Congenital Hydronephrosis in Infants Aged 0-6 Months |
| NCT07581223 | Not specified | NOT_YET_RECRUITING | Integrating an AI-Driven Hydronephrosis Decision-Making Tool |
| NCT01330511 | Not specified | COMPLETED | Simplified Diagnostic Algorithm for Evaluation of Neonates With Prenatally Detected Hydronephrosis |
| NCT05087537 | Not specified | UNKNOWN | Effect of Concomitant Bladder Neck Incision and Urethral Valve Ablation on Surgical Re-intervention Rate for Patients With Posterior Urethral Valve |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| ETOMIDATE | 4 | 1 |
| MIDAZOLAM | 4 | 1 |
| PROPOFOL | 4 | 1 |
| S-ETOMIDATE | -1 | 1 |